| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1657* | 2020 |
| Whole–genome characterization of chemoresistant ovarian cancer AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ... Nature 521 (7553), 489-494, 2015 | 1475 | 2015 |
| Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes SC Dentro, I Leshchiner, K Haase, M Tarabichi, J Wintersinger, ... Cell 184 (8), 2239-2254. e39, 2021 | 281 | 2021 |
| Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer EL Christie, S Fereday, K Doig, S Pattnaik, SJ Dawson, DDL Bowtell Journal of Clinical Oncology 35 (12), 1274-1280, 2017 | 187 | 2017 |
| Acquired chemotherapy resistance in ovarian cancer EL Christie, DDL Bowtell Annals of Oncology 28, viii13-viii15, 2017 | 164 | 2017 |
| Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer EL Christie, S Pattnaik, J Beach, A Copeland, N Rashoo, S Fereday, ... Nature communications 10 (1), 1295, 2019 | 144 | 2019 |
| Mechanisms of drug resistance in high-grade serous ovarian cancer AE Freimund, JA Beach, EL Christie, DDL Bowtell Hematology/Oncology Clinics 32 (6), 983-996, 2018 | 113 | 2018 |
| LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin PA Cowin, J George, S Fereday, E Loehrer, P Van Loo, C Cullinane, ... Cancer research 72 (16), 4060-4073, 2012 | 111 | 2012 |
| A community-based model of rapid autopsy in end-stage cancer patients K Alsop, H Thorne, S Sandhu, A Hamilton, C Mintoff, E Christie, O Spruyt, ... Nature biotechnology 34 (10), 1010-1014, 2016 | 83 | 2016 |
| Homologous recombination DNA repair pathway disruption and retinoblastoma protein loss are associated with exceptional survival in high-grade serous ovarian cancer DW Garsed, K Alsop, S Fereday, C Emmanuel, CJ Kennedy, ... Clinical Cancer Research 24 (3), 569-580, 2018 | 75 | 2018 |
| EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas D Etemadmoghadam, WJ Azar, Y Lei, T Moujaber, DW Garsed, ... Cancer research 77 (16), 4268-4278, 2017 | 74 | 2017 |
| Ovarian carcinoma-associated mesenchymal stem cells arise from tissue-specific normal stroma LG Coffman, AT Pearson, LG Frisbie, Z Freeman, E Christie, DD Bowtell, ... Stem Cells 37 (2), 257-269, 2019 | 66 | 2019 |
| Abnormal nuclear pore formation triggers apoptosis in the intestinal epithelium of elys-deficient zebrafish TA de Jong–Curtain, AC Parslow, AJ Trotter, NE Hall, H Verkade, ... Gastroenterology 136 (3), 902-911. e7, 2009 | 47 | 2009 |
| Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer T O’Donnell, EL Christie, A Ahuja, J Buros, BA Aksoy, DDL Bowtell, ... BMC cancer 18, 1-11, 2018 | 43 | 2018 |
| Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer N Rinne, EL Christie, A Ardasheva, CH Kwok, N Demchenko, C Low, ... Cancer Drug Resistance 4 (3), 573, 2021 | 40 | 2021 |
| Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer EH Stover, MB Baco, O Cohen, YY Li, EL Christie, M Bagul, A Goodale, ... Molecular Cancer Research 17 (11), 2281-2293, 2019 | 33 | 2019 |
| The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer DW Garsed, A Pandey, S Fereday, CJ Kennedy, K Takahashi, K Alsop, ... Nature genetics 54 (12), 1853-1864, 2022 | 30 | 2022 |
| Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer A Nath, PA Cosgrove, H Mirsafian, EL Christie, L Pflieger, B Copeland, ... Nature communications 12 (1), 3039, 2021 | 28 | 2021 |
| Tumor-derived MMPs regulate cachexia in a Drosophila cancer model W Lodge, M Zavortink, S Golenkina, F Froldi, C Dark, S Cheung, ... Developmental Cell 56 (18), 2664-2680. e6, 2021 | 25 | 2021 |
| Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer NL Burdett, MO Willis, K Alsop, AL Hunt, A Pandey, PT Hamilton, T Abulez, ... Nature genetics 55 (3), 437-450, 2023 | 17 | 2023 |
